Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With
174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a biomedical technology research
and development company that patents, designs, develops and
commercializes innovative diagnostic and therapeutic injection
technologies and instruments for medical, dental, cosmetic and
veterinary applications. Milestone's computer-controlled systems are
designed to make injections precise, efficient, and virtually painless.
Milestone’s proprietary DPS® Dynamic Pressure Sensing
technology® platform advances the development of next-generation
devices, regulating flow rate and monitoring pressure from the tip of
the needle, through platform extensions for local anesthesia for
subcutaneous drug delivery, with specific applications for cosmetic
botulinum toxin injections, epidural space identification in regional
anesthesia procedures, and intra-articular joint injections.
RETINA COMPANY SHOWCASE- Ocular TherapeutixHealthegy
Presentation by Ocular Therapeutix at OIS@ASRS 2016.
Participant:
Jonathan Talamo, MD, Chief Medical Officer- Ocular Therapeutix
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ocular TherapeutixHealthegy
Posterior Segment Company Showcase - Ocular Therapeutix at OIS@AAO 2016.
Presenter:
Amar Sawhney, PhD, President, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - OptheaHealthegy
Posterior Segment Company Showcase - Opthea at OIS@AAO 2016.
Presenter:
Megan Baldwin, PhD, CEO & Managing Director
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer controlled
systems make injections precise, efficient, and
virtually painless.
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a biomedical technology research
and development company that patents, designs, develops and
commercializes innovative diagnostic and therapeutic injection
technologies and instruments for medical, dental, cosmetic and
veterinary applications. Milestone's computer-controlled systems are
designed to make injections precise, efficient, and virtually painless.
Milestone’s proprietary DPS® Dynamic Pressure Sensing
technology® platform advances the development of next-generation
devices, regulating flow rate and monitoring pressure from the tip of
the needle, through platform extensions for local anesthesia for
subcutaneous drug delivery, with specific applications for cosmetic
botulinum toxin injections, epidural space identification in regional
anesthesia procedures, and intra-articular joint injections.
RETINA COMPANY SHOWCASE- Ocular TherapeutixHealthegy
Presentation by Ocular Therapeutix at OIS@ASRS 2016.
Participant:
Jonathan Talamo, MD, Chief Medical Officer- Ocular Therapeutix
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - Ocular TherapeutixHealthegy
Posterior Segment Company Showcase - Ocular Therapeutix at OIS@AAO 2016.
Presenter:
Amar Sawhney, PhD, President, CEO & Chairman
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Posterior Segment Company Showcase - OptheaHealthegy
Posterior Segment Company Showcase - Opthea at OIS@AAO 2016.
Presenter:
Megan Baldwin, PhD, CEO & Managing Director
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
IntelGenX Investor Presentation March 30 2017 ItelGenx
The presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia drugs. It also highlights a repurposed montelukast film for mild cognitive impairment currently in clinical trials. The presentation outlines IntelGenx's business strategy, partnership with Chemo, new manufacturing facility, and management team. It concludes that IntelGenx has a solid platform for growth due to its significant market potential and ability to build strategic partnerships.
IntelGenx is an innovative pharmaceutical film company presenting its product pipeline and technology platforms to investors. The presentation discusses IntelGenx's oral thin film and buccal film technologies, product development strategies, business model, pipeline of products including treatments for migraines, erectile dysfunction, and brain degenerative diseases, and clinical trial results. It highlights a de-risked product candidate using montelukast to treat brain degenerative diseases and significant market opportunities for its pipeline products.
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's strategy to develop and commercialize improved drug delivery products using its oral thin film platform. Key points include successful commercial partnerships, a robust product pipeline including generic and branded products, positive clinical trial results, and a new manufacturing facility positioned for growth. Financial results show increasing revenue and adjusted EBITDA. The presentation positions IntelGenx as a leader in oral thin films with innovative technology and a clear strategy for growth.
IntelGenx is a drug delivery company that develops improved versions of approved drugs using its proprietary drug delivery platforms, VersaFilm and AdVersa. Some of its pipeline products include Rizaport for migraines, Tadalafil VersaFilm for erectile dysfunction, Loxapine VersaFilm for schizophrenia, and Montelukast VersaFilm for mild cognitive impairment. The company has completed clinical trials demonstrating its products offer benefits over existing drugs such as increased bioavailability and reduced side effects. IntelGenx licenses its products to partners and retains manufacturing rights to generate revenue through milestone payments and royalties.
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Actavis plc is proposing to acquire Durata Therapeuticals Inc. Durata developed Dalbavancin, a novel antibiotic, and received FDA approval in 2014. The acquisition would strengthen Actavis' infectious disease portfolio. Valuation analyses indicate a purchase price range of $18.5-$28.7 per share, representing a 26-95% premium over Durata's current stock price. The acquisition is likely to proceed given strategic fit and friendly shareholder base.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's pipeline of oral thin film products, including products for migraines, erectile dysfunction, schizophrenia/bipolar disorder, and mild cognitive impairment. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance. It concludes that IntelGenx has established a solid platform for growth by leveraging its oral thin film technology and implementing a product sourcing strategy to identify high-value opportunities.
Anterior Segment Company Showcase - Novaliq GmbHHealthegy
Novaliq has developed an artificial tear product called NovaTears/EvoTears that addresses the lipid layer of the tear film. It has been successfully launched in Europe. Novaliq is also developing treatments for dry eye, glaucoma, and retinal diseases using their proprietary EyeSol technology platform. Their pipeline includes products in development, clinical trials, and regulatory review.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia/bipolar drugs. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and financial performance over recent years. It positions IntelGenx for continued growth by leveraging its drug delivery platform and oral thin film technology.
IntelGenx March 13, 2017 Investor PresentationItelGenx
This presentation provides an overview of IntelGenx Corp., a drug delivery company focused on oral thin film technologies. Key points include:
- IntelGenx has a pipeline of product candidates using its VersaFilm drug delivery technology, including products for migraines, erectile dysfunction, schizophrenia, and repurposing drugs for brain diseases.
- The company has completed construction of a new manufacturing facility to produce oral thin films and lower costs.
- Management believes IntelGenx is well positioned for growth due to its drug delivery expertise, business model focusing on drug repurposing and first-to-file generics, and competitive manufacturing capabilities.
This document provides a summary of key events and developments in ophthalmology in 2015. It discusses growth in attendance at major ophthalmology conferences, FDA drug and device approvals, positive results from phase 3 trials of gene therapy for RPE65-mediated retinal dystrophy and Humira for uveitis. It also reviews trends in the use of anti-VEGF drugs to treat wet AMD, global rates of IVT injections, the ophthalmic drug market, and causes of blindness worldwide. Tables and graphs are included to illustrate drugs, procedures, technologies, and market data.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. is a leading developer of computerized drug delivery instruments that provide painless injections. They have entered the large worldwide dental market and believe their pressure force feedback and pulse wave technologies will help improve healthcare outcomes at lower costs across multiple medical areas. Recent studies showed their CompuFlo epidural instrument can save over $500 per hospital stay on average. New CompuWave and CathCheck features allow verification of epidural and catheter placement in real time, saving significant time and costs compared to traditional techniques. Milestone sees opportunities in peripheral nerve blocks, thoracic catheters, intra-articular injections and more, supported by their expanding patent portfolio.
Ebers and biogaran innovation challengeFacundo Noya
Ebers is a startup specialized in diabetic foot care and prevention. Our principal solution are smart insole that combines pressure, temperature and humidity measure with algorithm to alert early for any risk to diabetic patients.
The New England Eye Center sees over 50,000 patient visits per year and performs over 1,700 surgeries. It requests funding for equipment to expand its retina service, replace aging ultrasound and visual field equipment, and add an autorefractor to increase efficiency and accommodate growing patient volumes. The investments are expected to generate additional revenue, improve patient outcomes and experience, and support the center's research activities.
Making Value-Based Healthcare in Cataract a Reality Insights from VBHCAT Pr...Alexandre Lourenço
Alexandre Lourenço's keynote on "Making Value-Based Healthcare in Cataract a Reality - Insights from VBHCAT Project in Portugal", at the 44th World Hospital Congress organized by the International Hospital Federation, in November 8th 2021.
John Ludlow presented on regenerative medicine past, present, and future. He discussed early work in organ transplantation and tissue engineering. Currently, there are over 50 companies developing regenerative medicine products and the field is starting to provide commercialized solutions. However, the path has not been straightforward. Moving forward, success may come from focusing on clinical and commercial viability, strategic intellectual property management, and iterative technology evolution driven by clinical needs. The future of regenerative medicine may include more personalized and rapid regenerative options.
This document discusses trends in the global healthcare industry and strategies for sustainability. It notes that healthcare spending is projected to triple globally by 2020 due to factors like aging populations and rising standards of living. However, patients often do not receive recommended care for common conditions and medical errors are a leading cause of death. The document outlines seven features of sustainable healthcare systems: establishing common ground; developing a digital infrastructure; realigning financial incentives; implementing quality standards; strategically deploying resources; fostering innovation; and enabling adaptable roles. It provides examples of countries that have implemented policies aligned with these features to control costs while improving outcomes.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
IntelGenX Investor Presentation March 30 2017 ItelGenx
The presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia drugs. It also highlights a repurposed montelukast film for mild cognitive impairment currently in clinical trials. The presentation outlines IntelGenx's business strategy, partnership with Chemo, new manufacturing facility, and management team. It concludes that IntelGenx has a solid platform for growth due to its significant market potential and ability to build strategic partnerships.
IntelGenx is an innovative pharmaceutical film company presenting its product pipeline and technology platforms to investors. The presentation discusses IntelGenx's oral thin film and buccal film technologies, product development strategies, business model, pipeline of products including treatments for migraines, erectile dysfunction, and brain degenerative diseases, and clinical trial results. It highlights a de-risked product candidate using montelukast to treat brain degenerative diseases and significant market opportunities for its pipeline products.
The presentation summarizes IntelGenx, a drug delivery company focused on oral thin film technologies. It discusses IntelGenx's strategy to develop and commercialize improved drug delivery products using its oral thin film platform. Key points include successful commercial partnerships, a robust product pipeline including generic and branded products, positive clinical trial results, and a new manufacturing facility positioned for growth. Financial results show increasing revenue and adjusted EBITDA. The presentation positions IntelGenx as a leader in oral thin films with innovative technology and a clear strategy for growth.
IntelGenx is a drug delivery company that develops improved versions of approved drugs using its proprietary drug delivery platforms, VersaFilm and AdVersa. Some of its pipeline products include Rizaport for migraines, Tadalafil VersaFilm for erectile dysfunction, Loxapine VersaFilm for schizophrenia, and Montelukast VersaFilm for mild cognitive impairment. The company has completed clinical trials demonstrating its products offer benefits over existing drugs such as increased bioavailability and reduced side effects. IntelGenx licenses its products to partners and retains manufacturing rights to generate revenue through milestone payments and royalties.
Public Device & Biopharma Ophthalmology Company Showcase - QLTHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - QLT at OIS@AAO 2016.
Presenter:
David Saperstein, MD, Chief Medical Advisor
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Actavis plc is proposing to acquire Durata Therapeuticals Inc. Durata developed Dalbavancin, a novel antibiotic, and received FDA approval in 2014. The acquisition would strengthen Actavis' infectious disease portfolio. Valuation analyses indicate a purchase price range of $18.5-$28.7 per share, representing a 26-95% premium over Durata's current stock price. The acquisition is likely to proceed given strategic fit and friendly shareholder base.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's pipeline of oral thin film products, including products for migraines, erectile dysfunction, schizophrenia/bipolar disorder, and mild cognitive impairment. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance. It concludes that IntelGenx has established a solid platform for growth by leveraging its oral thin film technology and implementing a product sourcing strategy to identify high-value opportunities.
Anterior Segment Company Showcase - Novaliq GmbHHealthegy
Novaliq has developed an artificial tear product called NovaTears/EvoTears that addresses the lipid layer of the tear film. It has been successfully launched in Europe. Novaliq is also developing treatments for dry eye, glaucoma, and retinal diseases using their proprietary EyeSol technology platform. Their pipeline includes products in development, clinical trials, and regulatory review.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia/bipolar drugs. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and financial performance over recent years. It positions IntelGenx for continued growth by leveraging its drug delivery platform and oral thin film technology.
IntelGenx March 13, 2017 Investor PresentationItelGenx
This presentation provides an overview of IntelGenx Corp., a drug delivery company focused on oral thin film technologies. Key points include:
- IntelGenx has a pipeline of product candidates using its VersaFilm drug delivery technology, including products for migraines, erectile dysfunction, schizophrenia, and repurposing drugs for brain diseases.
- The company has completed construction of a new manufacturing facility to produce oral thin films and lower costs.
- Management believes IntelGenx is well positioned for growth due to its drug delivery expertise, business model focusing on drug repurposing and first-to-file generics, and competitive manufacturing capabilities.
This document provides a summary of key events and developments in ophthalmology in 2015. It discusses growth in attendance at major ophthalmology conferences, FDA drug and device approvals, positive results from phase 3 trials of gene therapy for RPE65-mediated retinal dystrophy and Humira for uveitis. It also reviews trends in the use of anti-VEGF drugs to treat wet AMD, global rates of IVT injections, the ophthalmic drug market, and causes of blindness worldwide. Tables and graphs are included to illustrate drugs, procedures, technologies, and market data.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Milestone Scientific Inc. is a leading developer of computerized drug delivery instruments that provide painless injections. They have entered the large worldwide dental market and believe their pressure force feedback and pulse wave technologies will help improve healthcare outcomes at lower costs across multiple medical areas. Recent studies showed their CompuFlo epidural instrument can save over $500 per hospital stay on average. New CompuWave and CathCheck features allow verification of epidural and catheter placement in real time, saving significant time and costs compared to traditional techniques. Milestone sees opportunities in peripheral nerve blocks, thoracic catheters, intra-articular injections and more, supported by their expanding patent portfolio.
Ebers and biogaran innovation challengeFacundo Noya
Ebers is a startup specialized in diabetic foot care and prevention. Our principal solution are smart insole that combines pressure, temperature and humidity measure with algorithm to alert early for any risk to diabetic patients.
The New England Eye Center sees over 50,000 patient visits per year and performs over 1,700 surgeries. It requests funding for equipment to expand its retina service, replace aging ultrasound and visual field equipment, and add an autorefractor to increase efficiency and accommodate growing patient volumes. The investments are expected to generate additional revenue, improve patient outcomes and experience, and support the center's research activities.
Making Value-Based Healthcare in Cataract a Reality Insights from VBHCAT Pr...Alexandre Lourenço
Alexandre Lourenço's keynote on "Making Value-Based Healthcare in Cataract a Reality - Insights from VBHCAT Project in Portugal", at the 44th World Hospital Congress organized by the International Hospital Federation, in November 8th 2021.
John Ludlow presented on regenerative medicine past, present, and future. He discussed early work in organ transplantation and tissue engineering. Currently, there are over 50 companies developing regenerative medicine products and the field is starting to provide commercialized solutions. However, the path has not been straightforward. Moving forward, success may come from focusing on clinical and commercial viability, strategic intellectual property management, and iterative technology evolution driven by clinical needs. The future of regenerative medicine may include more personalized and rapid regenerative options.
This document discusses trends in the global healthcare industry and strategies for sustainability. It notes that healthcare spending is projected to triple globally by 2020 due to factors like aging populations and rising standards of living. However, patients often do not receive recommended care for common conditions and medical errors are a leading cause of death. The document outlines seven features of sustainable healthcare systems: establishing common ground; developing a digital infrastructure; realigning financial incentives; implementing quality standards; strategically deploying resources; fostering innovation; and enabling adaptable roles. It provides examples of countries that have implemented policies aligned with these features to control costs while improving outcomes.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
This presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's focus on using oral thin film technology to improve drug delivery and its product pipeline, which includes films for migraines, erectile dysfunction, schizophrenia, and mild cognitive impairment. The presentation also provides financial results, noting revenue growth and net income, as well as IntelGenx's new manufacturing facility and strengthened management team.
III Edició "The British Experience in Technologies for Health". Hospital de Sant Pau, Barcelona. 9 de novembre de 2011. Esdeveniment organitzat per la Fundació TICSalut i el Departament de Comerç i Inversions del Consolat General Britànic a Barcelona, UK Trade & Investment, per posar en contacte oportunitats i coneixements entre el Regne Unit i Catalunya.
The document discusses the UK medical device market and the NHS. It describes M3AT's attempts to develop and fast track innovative medical devices to NHS patients. Specifically, it discusses M3AT's development of Urocomfor, a new urine management system. Urocomfor provides benefits to patients by improving autonomy and dignity. It benefits nurses by freeing them from unnecessary tasks. For hospitals, it can reduce costs from infections and accidents while improving patient satisfaction. However, start-up companies like M3AT find it difficult to get innovative devices through the NHS supply chain process and contracts.
9th European Patients' Rights Day - Tom Kelley, European Director Internation...Cittadinanzattiva onlus
This document provides information about the International Consortium for Health Outcomes Measurement (ICHOM). ICHOM works to define standard sets of outcomes measures for medical conditions that are important to patients. They organize international working groups of physicians, registry leaders, and patient representatives to develop these outcome measure standards. ICHOM then supports healthcare providers in implementing the standards and measuring outcomes to ultimately allow for benchmarking of value, defined as patient outcomes relative to the cost of achieving those outcomes.
This document discusses the development of a surgical simulation training system called ReSuture. It notes that surgical complications can be reduced by 50% with simulation training. ReSuture aims to provide a lifelike and cost-effective training platform for open vascular surgery using patent-pending lifelike materials and a pumping system to simulate blood flow. The startup is seeking $250k in funding to validate its first product, expand its advisory board, and market the simulation system to medical schools and hospitals to reduce errors and costs from avoidable complications in vascular surgery.
This document discusses the need for patient-centered clinical trials due to rising complexity, costs and failure rates of traditional trials. It notes delays in enrollment are a major issue, inflating costs and timelines. Protocols have become more complex and burdensome, reducing adherence and retention. The future requires improving recruitment methods, incorporating patient needs, and placing data generation in patients' hands through technologies like social media and ePRO tools. Patient-centered approaches may help address these challenges and better support drug development.
Glaukos Corporation is an ophthalmic medical technology company transforming glaucoma treatment. Their minimally-invasive micro-scale injectable therapies, including the iStent, provide more effective treatment options compared to eye drops and traditional surgeries. Clinical trials demonstrate the iStent used with cataract surgery significantly lowers intraocular pressure up to 3 years post-op while reducing medication use. Additional studies show promise for combination treatments and sustained efficacy of micro-scale injectable therapies.
The document discusses the development of a surgical simulation training system called ReSuture. It notes that surgical complications can be reduced by 50% with simulation training. ReSuture aims to provide a realistic and cost-effective training platform for open vascular surgery using lifelike materials and a pumping system to simulate blood flow. The startup is seeking $250,000 in funding to validate its first product, expand its advisory board, and market the simulation system to medical schools and hospitals to improve surgical training outcomes.
The document discusses guidelines for billing Medicare for traditional monofocal cataract surgery and premium intraocular lenses (IOLs) that correct presbyopia and astigmatism. It summarizes that Medicare now allows surgeons to bill patients for premium IOLs that correct vision beyond standard cataract surgery. Optometrists play an important role in managing these patients and referring them for premium IOLs, which has created new opportunities. Strict billing guidelines must be followed to comply with Medicare regulations.
Similar to Milestone Scientific Inc. Investor Presentation (20)
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a biotech company developing immune monitoring and immune modulation platforms. Its AditxtScore platform can provide comprehensive immune profiles to monitor responses to pathogens, vaccines, drugs and transplants. Its Adimune platform aims to modulate the immune system to treat conditions like psoriasis, type 1 diabetes, and increase skin allograft survival. The company is working to develop, operate and commercialize these platforms. It currently generates revenue from immune monitoring tests and expects revenue from licensing deals for immune modulation programs as they advance in clinical trials towards commercialization.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
2. Safe Harbor Statement
This presentation contains forward-looking statements regarding the timing
and financial impact of Milestone's ability to implement its business plan,
expected revenues, timing of regulatory approvals and future success. These
statements involve a number of risks and uncertainties and are based on
assumptions involving judgments with respect to future economic, competitive
and market conditions, future business decisions and regulatory developments,
all of which are difficult or impossible to predict accurately and many of which
are beyond Milestone's control. Some of the important factors that could cause
actual results to differ materially from those indicated by the forward-looking
statements are general economic conditions, failure to achieve expected
revenue growth, changes in our operating expenses, adverse patent rulings,
FDA or legal developments, competitive pressures, changes in customer and
market requirements and standards, and the risk factors detailed from time to
time in Milestone's periodic filings with the Securities and Exchange
Commission, including without limitation, Milestone's Annual Report for the
year ended December 31, 2019. The forward-looking statements in this
presentation are based upon management's reasonable belief as of the date
hereof. Milestone undertakes no obligation to revise or update publicly any
forward-looking statements for any reason.
2
3. Company History
With 174 foreign patents and 19 US patents
issued Milestone Scientific is the leader in
modern injection technology.
Milestone Scientific Inc. (MLSS) is a leading
medical research and development company
that designs and patents innovative injection
technology. Milestone's computer-controlled
systems make injections precise, efficient, and
virtually painless.
3
4. Why enter the Epidural Market?
Market Size
Epidural procedures are one of the fastest growing procedures in the US and worldwide. It is
estimated that over 11 million epidural procedures are performed each year in the US and over
30 million worldwide.
Over $5 billion is spent annually on epidural injections in the US alone. The approximate break
down of epidural procedures in the US is:
• 2.4 million labor procedures out of almost 4 million births
• 9 million pain intervention steroid injections
• Neuroaxial Regional Blocks for hip and knee surgeries
~900,000 total and growing
4
5. Current technology being used today!
The technique of "single-shot" lumbar
epidural anesthesia was first developed
in 1921 by Spanish military surgeon
Fidel Pagés, and hasn’t changed
significantly since.
Glass Loss of Resistance
(LOR)
1946
“Modern” LOR
Syringes
5
6. Innovating a New Standard of Care
in Anesthesia
• Now with our patented
CompuWave™ and CathCheck™
features, anesthesiologists should be
able to save significant time and
institutions should save significant
costs
• Correlates subjective feel with
objective visual and audible
verification of pressure changes
• Offers real-time needle location with
consistent distinction of true loss of
resistance
• Builds physician confidence resulting
in fewer attempts; less Dural
punctures reducing complications
and costs
• Accelerates procedure learning curve
for residents and trainees
Welcome to the 21st
Century
6
7. LISTENING TO PROVIDERS,
ADDRESSING UNMET NEEDS
• Placement of an epidural needle is difficult;
Requiring 60-90 placements before
reaching an adequate skill level
• 17% of failure rates are due to false loss of
resistance (False Loss of resistance is when
the needle enters soft tissue or fatty tissue
and the provider believes it is in the
epidural space when it is not) resulting in a
failure to provide pain relief. This requires
another attempt while the patient remains
in labor and pain.
• Epidural Dural punctures are as high as
5+%. An Epidural puncture is when the
Dura is breached and the needle enters
into the spinal canal, causing cerebral
spinal fluid to leak resulting in headaches,
pain, infection, and other morbidities
costing insurance companies and hospitals
additional time and money.
• 20% of epidural blood patches also fail
and require additional care ( A blood patch
is a procedure to try and repair the Dural
punctures)
7
8. 8
Management Team
Interim CEO
Leonard Osser
CFO/COO
Joseph D’Agostino
Over 76 years of collective commercial experience in medical with
Involvement in numerous medical product launches
9. CompuFlo Epidural Instrument
Commercial Momentum
• The CompuWave™ patented feature is
allowing precise location identification of
the epidural space
• Nine peer-reviewed published studies
validate instrument effectiveness in
identifying the epidural space
• Additional ongoing studies
• More than 2,000 epidural procedures
performed worldwide including key
opinion leaders
• Hospital in Italy adopts CompuFlo for all
epidurals in labor and delivery
• Moving to a direct sales model in the USA
9
10. New Clinical Trial Finds CompuFlo® Instrument a Safe
Alternative to Current Standards of Care
▪ 160 labor and delivery (L&D) patients –
400 total
▪ 99 % effective in identifying epidural
space on first attempt
▪ 14 % more successful in patients with
high BMI
▪ L&D epidurals resulted in 0 dural
punctures, loss of resistance 4 (old
technique being used today)
▪ Procedure time reduced by 1 minute with
CompuFlo
ANESTHESIA & ANALGESIA
NOV 2019
10
11. ANESTHESIOLOGY RESEARCH & PRACTICE
JAN 2019
▪ 120 patient clinical study
▪ CompuFlo blocks performed successfully with
no complications
▪ Consistent differentiation of true loss of
resistance
“The pressure sensing innovation
in CompuFlo offers a more
objective, reliable and simpler
way to identify the epidural
space. This confidence in
recognizing a true loss of
resistance can help improve the
efficacy of anesthesia, reduce
complications, and speed the
procedure learning curve for
trainees.”
Dr. Giorgio Capogna
Director of the European School
of Obstetric Anesthesia and
Maternal Neonatal Simulation
Center
11
12. INTERNATIONAL JOURNAL OF OBSTETRIC
ANESTHESIA
NOV 2018
▪ Objective identification of ligamentum flavum
and epidural space
▪ Difficult blocks rescued in a single attempt
▪ Differentiation of true loss of resistance for
accurate epidural placement
“We [have] validated the
CompuFlo device as a means of
adequately identifying the
ligamentum flavum and the
epidural space. “
“Our preliminary findings suggest
that it could assist the physician
in training when performing
epidural insertion.”
Study investigators from the Citta
di Roma Hospital and Careggi
Hospital:
Dr. Giorgio Capogna,
Dr. Michela Camorcia
Dr. Alessandra Coccoluto
Dr. Massimo Micaglio
Dr. Matteo Velardo12
13. Cost Savings Studies Underway
Large academic institution completed a definitive economic study
aimed to prove:
Significant reduction of accidental Dural punctures
Associated cost reduction
One anesthesiologist completed over 500 CompuFlo epidurals,
reporting no Dural punctures
KOL relationship development in progress in France, Spain,
Germany, UK, Belgium, Italy and USA
13
14. Financial Impact
Dural Puncture Reduction (Complications =More Costs)
▪Incident of accidental
Dural puncture is about
1-3% - more in laboring
women
▪Drastically under
reported
▪Blood patch failure rate
20% (Procedure used to
repair Dural puncture)
▪$8 to 12K per Dural
puncture
Annual Number of Live Births 3,000
Annual Number of Epidurals 1800
Dural Puncture Rate 3%
Annual Number of Dural Punctures 54
Dural Puncture Cost Per Incident $10,000
Additional days stay - mother 6,000
Additional days stay - baby 3,000
Imaging 500
Other costs 500
Annual Cost of Dural Punctures $540,000
Number of CompuFlo Instruments 1
CompuFlo Instrument Price ** 0
CompuFlo Disposable Cost $65
Total Cost of CompuFlo (1800 epidurals) $117,000
Cost Savings with CompuFlo
(Reducing # of punctures by 80 %) $338,000
Savings of more than 50%
14
15. Financial Impact
RESIDENT Dural Puncture Reduction
▪Resident Dural
puncture rate
as high as 5%
(some studies show as
high as 17%)
Annual Number of Live Births 3,000
Annual Number of Epidurals 1800
Dural Puncture Rate 5%
Annual Number of Dural Punctures 90
Dural Puncture Cost Per Incident $10,000
Additional days stay - mother 6,000
Additional days stay - baby 3,000
Imaging 500
Other costs 500
Annual Cost of Dural Punctures $900,000
Number of CompuFlo Instruments 1
CompuFlo Instrument Price ** 0
CompuFlo Disposable Cost $65
Total Cost of CompuFlo (1800 epidurals) $117,000
Cost Savings with CompuFlo
(Reducing # of punctures by 80 %) $626,000
Savings of more than 65%
15
16. Sales strategy
Establish CompuFlo as the
preferred procedure using the
cost saving analysis
Gaining access to large GPO’s
Vizient- 5,200 Hospitals
Premier- 3,750 Hospitals
Itare- 3,500 hospitals
Moving to a direct sales force
with clinical support personnel
US Sales
16
Over 200 physician demo’s
completed in over 16 hospitals
Given the significant reduction of
time that CathCheck™ affords
anesthesiologists, we believe that
this will be our first point of entry
into the US hospital market.
17. International Sales
Addition of MOVI Group in Italy
10 instruments purchased
28 sales agents in the field
1 dedicated product manager,
3 regional managers
First sale by MOVI to Ospedale
“Pugliese Ciaccio” di
Cantanzaro, hospital in Italy
Agreement with new Croatian
distributor, EMA d.o.o.
3 instruments purchased
Trials in 4 hospitals
Sales to Algeria, Diagal
6 instruments
Lebanon distributor, Sterimed
Presented CompuFlo at 3
congresses
Trials in 2 University Hospitals
in progress
MOU with Russian distirbutor, REAN
1 demo instrument sold to
investigate market size and
potential
Presented at 4 congresses
17
18. Marketing
• Refined market messaging to
providers
• Invested in US live birth data by
hospital for sales targeting
• Developed Cost Calculator App for
sales team
• Launched a Commercial Procedure
Tracker & Reporting Tool for loaner
trials
• Updating marketing and sales
brochures
• Developed CompuFlo Trainer
product to target simulation Labs &
Medical Training Centers
• Launching CompuWave™ and
CathCheck™ features
18
20. BEYOND EPIDURAL:
THE MEDICAL OPPORTUNITY
Peripheral
Nerve Block
Thoracic
Catheter
Check
Intra-articular
✓ Now with our patented CompuWave™ technology the
CompuFlo Epidural Instrument can now check catheters
in seconds not 20-40 minutes.
✓ High-risk nature of procedure; 3 – 5 % of all epidurals,
Study currently underway.
✓ Received peripheral nerve block patent
✓ Large worldwide market for injections into the joints
✓ Received Botox Patent in Jan 2020Botox
20
21. BUSINESS PLAN SUMMARY/STRATEGY
With the market and individual hospital systems all having different criteria
and purchasing models, we will have 3 different sales strategies.
1. Sell the CompuFlo instrument and disposables.
2. Consign the CompuFlo instrument and upcharge the disposables.
3. Lease the CompuFlo instrument and disposables, we include the
instrument and a minimum number of disposables into a monthly payment.
More disposables can be purchased if they exceed the minimum.
The strategy is to accommodate the different hospital systems purchasing
procedures. If consigned or leased it is a different process for the hospital,
often easier and less time consuming. Often a less time consuming process is
available if the product is consigned or leased to a hospital.
21
22. Milestone Scientific- Market Re-Cap
Epidural is one of the fastest growing segments in Medicine-
• 11 million performed in the US and 30 million worldwide
• 2.4 million Labor and Delivery- US
• 9 million nerve blocks for pain intervention- US
• 900,000+ for pain blocks in Hips and Knees- US
• Over a $5+ Billion Dollar Market in the US and growing
Peripheral Nerve Blocks
• Globally there are 41 million Peripheral Nerve blocks performed, US market is
expected to reach $430 Million by 2027. ( Milestone Scientific currently has a
study being conducted by Dr. Oliver Choquet at the Lapeyronie University
Hospital -Montpellier, France )
• With the passing of the Substance Abuse Disorder Prevention That Promotes Opioid
Recovery and Treatment for Patients and Communities (SUPPORT) act, physicians are
using more pain blocks to reduce the opioid use post surgery.
Insurance companies now require at least 3 pain injections for prognostic and diagnostic
workup prior to approving surgery in orthopedics and spine.
22
23. Two New Features added to the CompuFlo Epidural
Instrument
With the addition of the patented CompuWave™ technology we can
now not only verify epidural placement but also confirm catheter
placement in real time with the patients’ pulse.
23
24. What do these new features mean?
When performing an
epidural the CompuFlo™
instrument objectively
identifies the False Loss of
Resistance and True Loss of
Resistance. CompuWave™
allows the practitioner to
also verify that the needle
is in the epidural space
when the pulsatile
waveform is displayed
False Loss
of
Resistance
True Loss of
Resistance
24
25. What do these new features mean?
Until now clinicians check
catheters by administering a
bolus of anesthetic to a patient
and are then required to wait
20-40 minutes to see if the
patient’s pain has subsided, if it
doesn’t the catheter has to be
removed and another epidural
must be performed in order to
place a new catheter in the
epidural space.
With CathCheck™
identification and affirmation
that the catheter is either
placed in the epidural space or
not is achieved in seconds. This
saves considerable time and
money and provides better
patient care.
If the Catheter is in the
epidural space the
waveform indicates it. If it’s
not that will be indicated
as well.
25
26. The importance of CathCheck™
The CathCheck™ feature is unique to Milestone Scientific…the ability
to check catheters is reduced to seconds from 20 – 40 minutes.
CathCheck™ will allow much faster verification of the catheter
placement. Patients are often moved multiple times daily which can
lead to the catheter being dislodged from the epidural space. The
dislodgement of the catheter prevents the patients from receiving pain
relief. CathCheck™ is significantly reducing catheter placement
verification. CathCheck™’s ability for fast verification will considerably
reduce anesthesiologists’ time which will translate into considerable
savings to the institution and better patient care.
26